FMS樣酪氨酸激酶3(Flt3)多克隆抗體
Polyclonal Antibody to FMS Like Tyrosine Kinase 3 (Flt3)
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
- 編號PAA039Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA039Mu01-FMS樣酪氨酸激酶3(Flt3)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度0.5mg/ml
- 且適物種Homo sapiens (Human,人), Rattus norvegicus (Rat,大鼠)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 583 ¥ 1361 ¥ 1944 ¥ 4860 ¥ 19440
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對Flt3的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別Flt3。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA039Mu01 | FMS樣酪氨酸激酶3(Flt3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA039Mu01 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體 | WB; IHC; ICC; IP. |
LAA039Mu71 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Frontiers in physiology | Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303] |
PLoS One | Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and?… [Pubmed: 30235245] |
Bioscience Reports | N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858] |
Molecular Neurobiology | Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic?… [Doi: 10.1007/s12035-017-0835-5] |
Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
留言咨詢